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ABSTRAK 
 
Kehadiran sel leukemia yang minima merupakan penanda prognosis buruk pada pe-
sakit leukemia akut. Penganalisaan tahap bebas leukaemia secara sitometri aliran da-
pat menganggarkan baki minima sel leukaemia (MRD) selepas rawatan kemoterapi 
induksi pada pesakit kanak-kanak leukemia limfoblastik akut (ALL). Pesakit yang di-
katakan bebas dari leukaemia dengan analisa morfologi sum-sum tulang, di mana ka-
dar peratus limfoblas adalah kurang 5%, berkemungkinan besar masih mempunyai sel 
leukemia sebanyak 1010.  Walau bagaimana pun, kaedah imunofenotip sitometri aliran, 
boleh mengesan baki sel leukemia yang lebih rendah lagi (1 dalam 104 sel-sel) ber-
banding pemeriksaan morfologi sumsum tulang, dan ia boleh digunakan sebagai kae-
dah bagi menentukan MRD dan meramal kemungkinan leukemia akut berulang.  Ka-
jian ini adalah untuk membandingkan ciri-ciri klinikal dan hematologi pada kanak-ka-
nak yang mengalami ALL, dan juga untuk mengesan status MRD pesakit tersebut se-
cara sitometri aliran. Status MRD pesakit dianalisa pada hari ke-28, minggu ke-12 dan 
minggu ke-20 daripada rawatan kemoterapi induksi leukemia. Jangka hayat pesakit 
selepas lima tahun juga dikaji. Perbandingan status MRD secara morfologi sum-sum 
tulang dengan sitometri aliran telah dilakukan. Kajian ini telah dijalankan terhadap tiga 
puluh lapan kes kanak-kanak yang mengalami prekursor B-ALL di Pusat Perubatan 
UKM. Tidak terdapat perkaitan yang signifikan diantara ciri-ciri demografik, klinikal dan 
hematologi dengan status MRD  pada hari ke-28, namun terdapat perkaitan yang sig-
nifikan di antara status MRD yang positif secara sitometri aliran dengan keputusan 
morfologi sum-sum tulang pada minggu ke-12.  Tiga kes menunjukkan status MRD 
positif yang berterusan sehingga minggu ke-20 dan dua daripadanya telah relaps dan 
meninggal dunia. Dua puluh empat pesakit masih hidup selepas lima tahun. 
 
Kata kunci:  baki minima sel leukaemia (MRD), leukemia limfoblastik akut (ALL), sito-
metri aliran, imunofenotip 
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ABSTRACT  
 
Residual disease in patients with acute leukaemia indicates unfavorable prognosis. 
The evaluation of remission using flow cytometry allows a better estimation of minimal 
residual disease (MRD) after induction chemotherapy in childhood acute lymphoblastic 
leukaemia (ALL) cases. Patients in morphological marrow remission with presence of 
blast cells of less than 5%, may still have up to 1010 leukaemic cells. However with flow 
cytometric analysis, lower levels of the residual leukaemic cells  (1 in 104 cells) can be 
detected and it can be used as a tool to predict relapse. This study compared the 
presenting clinical and haematological features of children with ALL and their residual 
disease status determined by flow cytometry. Analysis of their MRD status following 
remission-induction chemotherapy were done at day-28, week-12 and week-20. The 
cases were also followed up to five years, to determine their survival status. Their 
residual disease status by flow cytometric immunophenotyping was also compared 
with their bone marrow findings morphologically. Thirty-eight cases of precursor B-ALL 
in pediatric patients from UKM Medical Centre (UKMMC) were analyzed. There was no 
significant correlation between demographic, clinical and haematological features with 
MRD status at day-28. However, there was a significant correlation between MRD 
status by flow cytometry and by morphological marrow examination at week-12. Three 
cases showed persistent MRD findings until week-20 where two of the cases relapsed 
and died subsequently.  Twenty four patients were still alive after five years of follow 
up. 
 
Key words:  minimal residual disease (MRD), acute lymphoblastic leukaemia (ALL), 
flow cytometry, immunophenotyping 
 
 
 
INTRODUCTION  
 
Monitoring of residual disease (MRD) in 
leukaemic patients offers a means of 
evaluating the efficacy of the treatment 
given. In childhood acute lymphoblastic 
leukaemia (ALL), relapses are reported 
in at least 20% of children who are 
treated with contemporary programs of 
chemotherapy. However, monitoring 
MRD in childhood ALL may create the 
possibility of tailoring treatment according 
to patient’s response, where a more in-
tensive therapy could be given to pa-
tients with high levels of MRD and a less 
intense one to those without MRD. Vari-
ous methods of detection of MRD in 
childhood precursor B-ALL, such as by 
morphology, karyotyping, in situ hybridi-
zation, immunofluorescence, cell culture, 
Southern blotting and polymerase chain 
reaction (PCR) analysis have been de-
scribed. However, the evaluation of resi-
dual disease in acute leukaemia is most 
often carried out by morphological analy-
sis of bone marrow aspirates with the 
criterion of free from residual disease 
(complete remission) denotes fewer  than 
5 % of blasts in the bone marrow cell 
population. Unfortunately, this method 
does not allow identification of low levels 
of the disease and patients in morpho-
logical remission may still have up to 1010 
leukaemia cells (Campana & Pui 1995; 
Campana 2003).   
Sensitive techniques to detect MRD 
may allow better estimation of the leu-
kaemia burden, provides information on 
residual disease and aids in therapeutic 
strategies. Flow cytometric detection of 
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MRD is based on the identification of 
immunophenotypic combination markers 
expressed on leukaemic cells but not on 
normal haemopoietic cells. It is based on 
the identification of uncommon pheno-
types or aberrant markers that are found 
at diagnosis. At certain points of time 
during and after chemotherapy, the same 
phenotypes or aberrant markers are 
analyzed and quantified. If expression of 
these markers is less than 1%, the pa-
tient is considered free from MRD. How-
ever, for the detection of a small number 
of leukaemic cells, a large number (105 - 
106) of cells is needed for screening. 
Thus flow cytometry can be used as a 
tool to predict relapse of leukaemia pa-
tients particularly when subsequent anal-
ysis of marrow MRD levels shows an in-
creasing trend. 
The close relationship between the size 
of tumour burden and the curability of 
acute leukaemia is well established. In 
ALL, a high white blood cell count (WBC) 
at diagnosis is indicative of a large tu-
mour mass and it is a poor prognostic 
indicator (Campana 2003, Pui & Crist 
1994). Other presenting features such as 
age, sex, lymphadenopathy, organome-
galy and the immunophenotype of blast 
cells are also known to have prognostic 
values in determination of remission in-
duction rate, remission duration and 
long-term survival of patients. Other pa-
rameters such as haemoglobin and 
platelet count may play some role; how-
ever, myeloid associated markers have 
been proven to have no adverse prog-
nostic significance in children (Pui et al. 
2008). These parameters have been 
used to classify patients into standard or 
high-risk groups before appropriate che-
motherapy is started. From previous stu-
dies, patients in the high-risk group that 
received standard risk of chemotherapy 
regime have a higher chance of relapse.  
The aim of this study was to establish 
the detection of residual disease by im-
munophenotyping using flow cytometry in 
childhood ALL during their induction and 
continuing chemotherapy. 
 
MATERIALS AND METHODS  
 
This descriptive cross sectional study 
was conducted in children with precursor 
B-ALL aged between one and 12 years, 
diagnosed in UKM Medical Centre 
(UKMMC) from June 2001 to October 
2003. It was carried out under a protocol 
approved by the Institutional Review and 
Ethics Committee. We obtained bone 
marrow samples from patients with in-
formed consent at diagnosis, and at vari-
ous time points that have been defined 
for standardized analysis of chemothe-
rapy treatment based on the UKALL 97 
protocol (Working Party On Leukaemia In 
Children, Revised November 1999). The 
time points of analysis were: following 
induction chemotherapy (day-28) and 
during the continuation therapy (week-12 
and week-20) for MRD assessment. The 
specimens of the patients were 
processed in the Haematology Unit, De-
partment of Pathology UKMMC. All pa-
tients were followed-up for five years to 
ascertain their survival status. 
Bone marrow smears were made from 
the marrow aspirations of the patients for 
morphological analysis and the remain-
ing of the marrow specimens were col-
lected in sterile ethylenediamine tetra-
acetic acid (EDTA) tubes for immuno-
phenotyping analysis. Differential counts 
of the patients from peripheral blood 
were also obtained at the same time. The 
marrow smears were stained for May-
Grunwald-Giemsa’s (MGG) and perox-
idase cytochemistry. The morphological 
assessments of bone marrow smears 
were observed by two Pathologists and 
the percentage of lymphoblasts were 
recorded. Mononuclear cells from bone 
marrow aspirates collected in EDTA, 
were separated on a density gradient 
using lymphoprep (HISTOPAQUE-1077), 
immunolabelled with a panel of mono-
MRD status in childhood ALL by flow cytometry  Med & Health 2010; 5(1): 22-33 
25 
 
Table 1: Demographic data of the precursor B-ALL 
patients 
 
Demography Number of cases 
Age  
< 2 years  7 (18.4%) 
2 – 10 years 28 (73.7%) 
> 10 years 3 (7.9%)
Sex  
Male 31 (81.0%) 
Female 7 (19.0%)
Race  
Malay 30 (78.9%) 
Chinese 5 (13.2%) 
Indian 3 (7.9%)
Total 38 
 
clonal antibodies conjugated with FITC 
and/or PE and analyzed by FACScan 
flowcytometer (Becton Dickinson) for 
immunophenotyping. Analyses of data 
were done using Cell Quest software 
(Becton Dickison).  
Diagnosis of precursor B-ALL was 
made based on the presence of surface 
expression of CD19 and cytoplasmic ex-
pression of CD 22 with negative cytop-
lasmic myeloperoxidase (MPO). The 
acute lymphoblastic leukaemia cases 
were included in the study if the blast 
cells expressed at least one of the fol-
lowing combined immunomarkers: 
 
i. CD19/CD34 
ii. CD33/CD19 
iii. CD13/CD19 
iv. CD33/CD10 
v. TdT 
 
For MRD detection, bone marrow sam-
ples from all patients during follow-up 
visits to the hospital were analyzed with 
the same immunomarkers that were 
present at diagnosis. Figures 1 and 2 
illustrate the examples of cases that were 
MRD positive and MRD negative respec-
tively. Morphological assessments were 
also compared with the flow cytometry 
immunophenotyping results. Bone mar-
row samples from pediatric cases of idi-
opathic thrombocytopenic purpura (ITP) 
and non-haematological malignancy 
without bone marrow involvement were 
used as controls.  
Demographic and clinical data such as 
age, sex, race, presence of lymphadeno-
pathy, hepatomegaly or splenomegaly 
and blood profile of the patients upon 
diagnosis and at day-28 post induction 
chemotherapy, were also recorded. 
 
RESULTS 
 
Sample population 
 
From June 2001 to October 2003, 49 
children aged one to 12 years with pre-
cursor B-ALL were diagnosed in 
UKMMC. However, minimal residual dis-
ease (MRD) could only be studied in only 
38 cases. Eleven children had to be ex-
cluded from the study because their bone 
marrow samples were not available at 
post chemotherapy or there were no 
suitable MRD markers detected at diag-
nosis. Table 1 shows the ranges of age, 
sex and race of patients in this study.  
 
Clinical findings at diagnosis 
 
Most of the children with precursor B-ALL 
presented with lymphadenopathy 
(76.3%), hepatomegaly (89.5%) and 
splenomegaly (76.3%). Some of these 
cases had very large liver and spleen 
(≥5.0 cm and below subcostal margin) 
i.e. 11 (28%) and 8 cases (21%) respec-
tively. 
 
White blood cells at diagnosis 
 
Table 2 illustrates the haematological 
characteristics of the patients at diagno-
sis. Most of the cases presented with 
white blood cell counts (WBC) of less 
than 50.0x109/L. Only four cases (10.5%) 
had WBC more than 50.0x109/L with the
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Figure 1: Flow cytometric analysis using two leukaemia-associated immunophenotypic markers showing 
presence of MRD (left – arrow) and absence of MRD (right). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Flow cytometric analysis using a single leukaemia-associated immunophenotypic marker showing 
presence of MRD (left – arrow) and absence of MRD (right). 
 
 
Table 2: Haemoglobin, white cell count, and platelet parameters of precursor B-ALL cases at diagnosis and 
at post remission induction chemotherapy 
 
 Minimum Maximum Mean 
At diagnosis 
          WBC x 10(9)/L 2 322 29.07 
          Hb g/dl 2.9 12.5 8.08 
          Platelet x 10(9)/L 7 405 83.8 
 
Post remission induction chemotherapy (Day 28) 
          WBC x 10(9)/L 1.0 16.1 6.2 
    
WBC – White blood cells, Hb – haemoglobin,  
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Table 3: Minimal residual disease (MRD) status of precursor B-ALL at day-28 post-induction chemotherapy 
and during continuation of chemotherapy (week-12 and week-20). 
 
MRD during continuation 
therapy MRD status MRD at end of  induction (Day-28) Week-12 Week-20 
Negative 19 25 23 
Positive 11 11 3 
ND / NA 8 2 12 
ND – not done; NA – not available 
 
highest count being 322.0x109/L (Table 
2) and the lowest WBC was 2.0x109/L. 
The mean WBC was 29.07x109/L.  Most 
of the patients showed significant reduc-
tion in the WBC at day-28 post chemo-
therapy. 
 
Residual leukaemic cells by flow 
cytometry (Table 3) 
 
Residual leukaemic cells (MRD) had 
been analyzed by flow cytometry at the 
specified points of time as mentioned 
earlier. However, only 30 cases at day-
28 of chemotherapy were available for 
MRD analysis, where 11 cases were 
found to be positive for MRD and 19 
cases had no residual disease.  At week-
12 of therapy, two cases had to be ex-
cluded due to inadequate marrow sam-
ples for MRD analysis but the number of 
cases that became negative for MRD 
had increased to 25 patients (69.0 %).   
However, at week-20, fewer samples 
were available for the analysis. There 
were inadequate specimens in ten pa-
tients, one patient had defaulted the fol-
low-up treatment and sought traditional 
medicine while another had succumbed 
to sepsis. 
 
Correlation between demographic, 
clinical and laboratory data of ALL cases 
at diagnosis and the residual disease 
(MRD) at day-28 of therapy 
 
There were only 30 cases for MRD as-
sessment at day-28 of chemotherapy 
(Table 4). There was no correlation be-
tween sex, race or age of the patients at 
diagnosis with MRD findings at day-28 
(p>0.05). There was no correlation be-
tween lymphadenopathy and hepatos-
plenomegaly at diagnosis with MRD at 
day-28 (p>0.05). Correlation between 
WBC, haemoglobin (Hb) and platelet 
counts at diagnosis with MRD at day-28 
were also not significant (p>0.05). Cases 
with a haemoglobin count of less than 
8g/dl and WBC of less than 50.0 x 109/L 
were negative for MRD. There was also 
no correlation between the immunophe-
notype of the blast cells and presence of 
myeloid aberrant markers  at diagnosis 
with MRD at day-28 (p>0.05). 
 
Correlation between morphological and 
flowcytometric assessments of residual 
disease (MRD) of ALL cases 
 
In this study, 35 cases achieved com-
plete marrow remission at day-28 of in-
duction chemotherapy by morphological 
examination. One case (Table 6; case 6) 
had a borderline blast cells percentage of 
5%. Analyses for MRD by flow cytometry 
at day-28 could be performed in only 30 
cases and 11 cases were found to be 
positive for MRD (Table 5) but the mor-
phological examination of their marrow 
specimens showed blast counts of less 
than 5%. 
For the week-12 analysis, bone marrow 
aspirations could be performed only on 
36 of 38 cases and the correlation be-
tween marrow findings and MRD at 
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Table 4: Correlation between the MRD status (at day-28 post-induction chemotherapy) and features of 
childhood ALL cases at diagnosis 
 
MRD at  day-28  
 
Number of 
cases % positive negative 
P 
Age (year)   
< 2 years 5 16.7 4 1 0.074 
2 - 10 years 24 80.0 7 17  
> 10 years 1 3.3  1  
Sex   
Male 23 76.7 9 14 0.612 
Female 7 23.3 2 5  
Race   
Malay 24 80.0 11 13 0.114 
Chinese  4 13.3 0 4  
Indian 2 6.7 0 2  
Immunophenotyping   
Common ALL 26 86.7 10 16 0.603 
Null 4 13.3 1 3  
Aberrant myeloid antigen   
present 17 56.7 5 12 0.346 
absent 13 43.3 6 7  
Lymph nodes   
present 23 76.7 10 13 0.161 
absent 7 23.3 1 6  
Liver   
≥ 5 cm 8 26.7 2 6 0.424 
< 5 cm 22 73.3 9 13  
Spleen   
≥ 5 cm 6 20.0 3 3 0.449 
< 5 cm 24 80.0 8 16  
Haemoglobin (Hb) at
diagnosis   
< 8 g/dl 18 60.0 6 12 0.750 
8 - 10 g/dl 6 20.0 2 4  
> 10 g/dl 6 20.0 3 3  
White cell count (WBC) at
diagnosis (x 109/L)   
< 50,000 28 93.3 11 17 0.265 
≥ 50,000 2 6.7 0 2  
Platelet count at diagnosis
(x 109/L)   
< 50,000 15 50.0 6 9 0.720 
50,000 - 100,000 8 26.7 2 6  
> 100,000 7 23.3 3 4  
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Table 5: Correlation between bone marrow (BM) morphology findings and status of minimal residual disease 
(MRD) at day-28 and week-12 post-induction chemotherapy. 
 
BM morphology at day 28 BM morphology at week 12 
MRD 
Blast < 5% Blast > 5% Blast < 5% Blast > 5% 
Negative 19 0 25 0 
Positive 11 0 9 2 
Total cases  30 0 34 2 
P  0.028 
  
week-12 was found to be statistically sig-
nificant (p<0.05). Flow cytometric analy-
sis at week-12 showed that there were 
nine cases with positive MRD although 
their morphological marrow assessments 
showed that the percentages of the blast 
cells were less than 5% (Table 5). One of 
the cases with positive MRD (case 6) 
had also not achieved complete marrow 
remission at day-28 (Table 6). Two cases 
were found to have blast cells of more 
than 5% of total nucleated cells by mor-
phological examination and they were 
also positive for MRD by flow cytometric 
analysis.  
 
Sequential determination of residual 
disease and survival  
 
There were only 3 cases (Case 1, 3 and 
6) with persistent MRD at week-20 of 
chemotherapy. These cases however, 
had no MRD assessment at day-28 (Ta-
ble 6). Case 1 and 3 had marrow remis-
sion morphologically at day-28 but case 
6 had borderline blast cell percentage 
(5%). Case 1 relapsed after one year 
while case 3 after six months of treat-
ment. Both succumbed to treatment 
complications.  To date, case 6 is still 
alive, which is more than 5 years after 
diagnosis.  
There were four cases with persistent 
MRD from day-28 until week-12 of ther-
apy but at week-20, three cases 
achieved a negative MRD status. How-
ever, MRD analysis could not be done on 
one case (case 38) due to insufficient 
sample. To date, only one patient (case 
5) had passed away after 3 years of di-
agnosis. 
There were 18 cases that were always 
negative for MRD. However, eight of 
them died within 12 weeks to 4 years af-
ter diagnosis. Case 8 had relapsed after 
3 years of treatment; case 39 had de-
faulted and relapsed while others re-
mained in remission but unfortunately 
had succumbed to sepsis. Twenty four 
patients were still alive after 5 years of 
follow up. 
 
DISCUSSION 
 
Acute lymphoblastic leukaemia (ALL) is 
the most common malignant disease-af-
fecting children and in Malaysia approx-
imately 75% of ALL cases are younger 
than 20 years of age (Lim et al. 2002). 
Most of the cases in this study were in 
the good prognostic age group i.e. two to 
ten years of age (73.7%) but majority of 
the cases were males (81%). A longer 
survival of cases in age group between 
two and ten years have been reported, 
which was more than one-and-a-half 
times as compared to patients  with age 
of less than two years or more than 10 
years, when  treated in an identical man-
ner (Pui et al. 2008). 
Gender has little or no impact on the 
success of remission induction and the 
relapse frequency during the first month 
of treatment. However, after discontinua-
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Table 6: Bone Marrow morphology and MRD status at post-induction chemotherapy, during continuation of 
therapy and survival status after 5 years.  
 
MRD Status 
Patient 
no. 
Marrow 
morphology  at 
day-28 
Marrow 
morphology 
at week-12 Day-28 Week-12 Week-20 
MRD markers 
Patient status 
after 5 years of 
diagnosis 
1 blast < 5% blast > 5% - Positive Positive TdT relapse /died 
2 blast < 5% blast < 5% - Negative Negative CD33/10 alive 
3 blast < 5% blast > 5% - Positive Positive TdT died 
5 blast < 5% blast < 5% Positive Positive Negative TdT died 
6 blast = 5% blast < 5% - Positive Positive TdT alive 
7 blast < 5% blast < 5% - Positive Negative CD19/34 alive 
8 blast < 5% blast < 5% Negative Negative Negative TdT relapse/died 
9 blast < 5% blast < 5% Positive Negative Negative TdT alive 
10 blast < 5% blast < 5% Negative Negative Negative TdT alive 
11 blast < 5% blast < 5% Negative Negative Negative CD19/34 died 
12 blast < 5% blast < 5% Positive Positive Negative CD19/34 alive 
13 blast < 5% blast < 5% Positive Negative Negative CD19/34 alive 
14 blast < 5% blast < 5% Positive Positive Negative TdT alive 
15 blast < 5% blast < 5% Positive Negative Negative CD33/10 alive 
16 blast < 5% blast < 5% Negative Negative Negative CD19/34 alive 
17 blast < 5% blast < 5% Negative Negative Negative CD33/10 alive 
18 blast < 5% blast < 5% Negative Negative Negative CD33/10 died 
19 blast < 5% blast < 5% Negative Negative Negative CD19/34 alive 
20 blast < 5% blast < 5% Positive Negative Negative CD33/10 alive 
21 blast < 5% blast < 5% Positive Negative Negative CD19/34 alive 
22 blast < 5% blast < 5% Negative Negative Negative CD33/10 alive 
26 blast < 5% blast < 5% Positive Negative Negative CD19/34 alive 
28 blast < 5% blast < 5% Negative Negative Negative CD19/34 alive 
29 blast < 5% blast < 5% Negative Negative Negative CD19/34 alive 
31 blast < 5% blast < 5% Positive Negative - CD19/34 unknown 
33 blast < 5% blast < 5% Negative Negative - TdT alive 
34 blast < 5% Inadequate Negative - - CD19/34 died 
35 inadequate. blast < 5% - Positive Negative CD19/34 
CNS 
relapsed/died 
37 .inadequate blast < 5% - Positive - CD19/34 alive 
38 blast < 5% blast < 5% Positive Positive - CD19/34 alive 
39 blast < 5% blast < 5% Negative Negative - CD19/34 Defaulted/died 
40 blast < 5% blast < 5% Negative Negative - TdT alive 
42 blast < 5% blast < 5% Negative Negative - CD33/19 
Gullain 
Barre/Chronic 
paralysis/died 
43 blast < 5% blast < 5% Negative Negative - TdT died 
44 Blast < 5% blast < 5% - Positive Negative TdT 
Relapsed and 
refused 
treatment/died 
46 blast < 5% blast < 5% Negative Negative - CD19/13 alive 
47 blast < 5% blast < 5% Negative Negative - CD33/10 died 
49 blast < 5% inadequate Negative - - TdT alive 
* (-) indicate no sample available. 
 
tion of therapy, boys continue to expe-
rience a higher incidence of relapse due 
to relapse in the testes as well as in the 
bone marrow (Chessells et al. 1995). In 
this study, 12 of 31 (38.7%) male pa-
tients had relapsed and died within five 
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years. The number of female patients 
involved in this study was small for a 
comparative study. 
Ethnically, the majority (78.9%) of the 
cases were Malays, followed by Chinese 
(13.2%) and Indians (7.9%). This obser-
vation is consistent with the data of the 
National Cancer Registry published in 
2002, where Malays have the highest 
incidence of leukaemias (Lim et al. 
2002).  
The sizes of peripheral lymph nodes, 
liver and spleen provide an indirect mea-
surement of leukaemic cell burden. Sev-
eral studies have demonstrated that 
massive lymphadenopathy; hepatome-
galy and splenomegaly adversely affect 
remission duration and survival (Ojala et 
al. 1995). However, mild to moderate in-
creases in the size of lymph nodes and 
abdominal organs do not appear to influ-
ence prognosis of ALL cases. In this 
study, most of the cases presented with 
lymphadenopathy (76.3%), hepatome-
galy (89.5%) and splenomegaly (76.3%), 
and enlarged liver and spleen of 5.0 cm 
or more were seen in 11 cases (28%) 
and 8 cases (21%) respectively.   
The total white blood cell count (WBC) 
at the time of diagnosis is the single most 
powerful determinant of remission induc-
tion, remission duration, and long-term 
survival for all age groups (Pui et al. 
2008). Patients with higher WBC at diag-
nosis have a higher risk for treatment 
failure than patients with lower WBC, and 
often have bulky extramedullary disease. 
WBC of more than 50.0 x 109/L is an in-
dication of poor prognosis (Pui et al. 
1998; Shu & Chen 2005).  
In this study, the clinical and haemato-
logical characteristics of children with 
ALL at diagnosis were compared with the 
residual disease status detected by flow 
cytometry, to assess for any correlation. 
MRD detection on completion of induc-
tion therapy was not significantly related 
to age, gender, race, lymphadenopathy 
and hepatosplenomegaly, leukocyte 
count, haemoglobin level, platelet count, 
immunophenotype of lymphoblast, and 
presence or absence of myeloid aberrant 
markers. It appears that the above fac-
tors could not be used to predict MRD 
status at day-28.  
Early clearance of leukaemic cells is a 
favourable prognostic indicator in child-
hood ALL. However, identification of re-
sidual leukaemic cells by light micro-
scopy is subjective and lacks sensitivity. 
Common therapeutic protocols have 
considered 5% of blast cells in the bone 
marrow as the morphologic limit for con-
sidering complete remission of ALL pa-
tients. Even though intensification of 
chemotherapy, risk stratification and 
supportive care have improved the out-
come of childhood ALL, 20% of children 
still succumb to relapse. Thus, a patient 
declared to be in complete clinical remis-
sion might, harbour as many as 1010 leu-
kaemic cells. The study of MRD has im-
proved the estimation of the number of 
blast cells present in the bone marrow 
during complete remission and during or 
after therapy. Thus it may be helpful to 
design a risk-adapted therapy in patients 
with acute leukaemia. The ability to 
detect residual leukaemic cells while they 
are still sensitive to treatment would al-
low for potentially curative intervention. 
The persistence of small numbers of leu-
kaemic cells post induction chemothe-
rapy in childhood ALL, indicates the re-
quirement of prolonged therapy (2.5 to 3 
years) to reduce the relapse hazard (Pui 
& Crist 1994; Hoelzer 1994). 
The sensitivity of MRD detection using 
flow cytometry depends on the numbers 
of cells analyzed and also on the MRD 
markers used. For optimal flow cytometry 
results it is imperative that the bone mar-
row specimen contain a large number of 
viable with a good separation of mono-
nuclear cells. The sample preparation 
and live gate acquisition should be per-
formed within 24 hours. If the samples 
have remained unprocessed for a longer 
Med & Health 2010; 5(1): 22-33  Azma R.Z. et al 
 
 32 
duration, there will be changes in the 
FSC/SSC pattern and the increasing 
population of dying or apoptotic cells will 
interfere with the analysis and interpreta-
tion of the results. Post chemotherapy 
bone marrow samples also have a large 
number of new regenerating normal lym-
phoid cells (haematogones) which may 
express CD34, CD19, CD10 and TdT 
and may affect the analysis of results 
(Coustan-Smith et al. 2006). 
We had used a two-color flow-cytome-
try for measurement of MRD. Patients 
with a high tumour burden at diagnosis 
and have MRD more than 1% post che-
motherapy are more likely to relapse 
early (Coustan-Smith et al. 2000). In this 
study, there were three cases with per-
sistent MRD positivity and the correlation 
study between marrow findings and MRD 
status at week-12 was found to be statis-
tically significant (p<0.05). Two of these 
patients had an early relapse and suc-
cumbed to the disease. Marrow remis-
sion status post chemotherapy of pa-
tients with MRD less than 1% were 
questionable (Coustan-Smith et al. 
2000). There were 18 cases in this study 
that had not shown MRD positivity at any 
point of time but eight of them died within 
a period of 12 weeks to 4 years after di-
agnosis.  
Coustan-Smith et al. (2006) showed 
that by using multi-coloured flow-cyto-
metry, MRD can be detected up to 0.01% 
and the cases that showed less than 
0.01% MRD positivity at the end of re-
mission induction are likely to have an 
excellent treatment outcome, compared 
to those with more than 0.01% (Coustan-
Smith et al. 2006).  
In the Paediatric Haemato-Oncology 
Unit UKMMC, stratification of intensive 
treatment usually depends on the pre-
senting WBC and age of the patient. 
Following induction chemotherapy, pa-
tients who had more than 5% of blast 
cells in the bone marrow morphologically 
and patients with nervous system (CNS) 
or testicular relapse will be given a more 
intensive chemotherapy regimen. Thus 
MRD analysis by flow cytometry can also 
be used to design a risk-adapted therapy 
in childhood ALL. The ability to detect 
residual leukaemic cells while they are 
still sensitive to treatment would allow 
more time, and potentially curative inter-
vention. The persistence of small num-
bers of leukaemic cells post induction 
chemotherapy in childhood ALL indicate 
the requirement of prolonged therapy 
(2.5 to 3 years) to reduce the relapse 
hazard (Campana 2003; Hoelzer 1994). 
This study was unable to prove that the 
risk of relapse was high in patients with 
persistent MRD since a few cases which 
were MRD negative also relapsed within 
4 years after diagnosis. 
 
CONCLUSION 
 
This study showed that there was no sig-
nificant correlation between MRD positiv-
ity by flow cytometry with the demo-
graphic, clinical or haematological data at 
diagnosis. However, there was a signifi-
cant correlation between MRD positivity 
by flow cytometry with morphological 
analysis of blast cells by light micro-
scopy. For better evaluation of MRD, a 
three or four  colour flow cytometry anal-
ysis should be used and a larger cohort 
of ALL cases are required, and would 
then aid in providing a basis for future 
clinical decision making in the manage-
ment of ALL cases. 
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